Tuberculosis Vaccine May Help Stop Multiple Sclerosis Development

Tuberculosis Vaccine May Help Multiple Sclerosis Development

A vaccine which is used to stop tuberculosis may also help in the prevention of the development of multiple sclerosis. MS is a disease that attacks the body’s central nervous system.

This new study was discovered when people who began to have the beginning symptoms of MS were given an injection of the tuberculosis vaccine.

This could be a handy, safe and cheap approach which would be available instantly following the very first symptoms that suggest a person could have MS, explained the research lead scientist Dr. Giovanni Ristori. He works at the Center for Experimental Neurological Therapies in Rome.

However, the study authors warned that there is more research needed to be done before the tuberculosis vaccine could be used long-term against multiple sclerosis, or in the majority of MS sufferers.

In individuals who have MS, the immune system ends up attacking the body’s healthy cells located in the central nervous system. Some of these include the spinal cord and brain.

Some of the first signs of multiple sclerosis are problems with vision, feelings of numbing in the body extremities, loss of hearing and balance. Close to one-fourth of people who experience these symptoms go on to develop MS within three years, Ristori stated.

The research study, which was printed Dec. 4 in the journal Neurology, included 73 people who suffered from these symptoms. 34 individuals received the tuberculosis vaccine and the remaining people in the group were given a placebo injection. The tuberculosis vaccine was a live vaccine not generally used in America.

The applicants received monthly MRI scans of their respective brains for the first six months of the research study. Scientists were looking for any lesions that were associated with multiple sclerosis. For the next 12 months, the study individuals received a drug that was already given to people who had MS. After that, they got whatever treatment that was suggested by their own neurologists. After about five years, the applicants were examined again to see if they had come down with MS.

After about six months, the scientists discovered there was an average of around eight brain lesions, which is a possible MS sign, in people who had gotten the placebo drug. This was in comparison to about three in the individuals who had gotten the vaccine.

After approximately five years, about 70 percent of the participants who had received the placebo had come down with multiple sclerosis. This was in comparison to about 40 percent who had been given the vaccine. There were no reports of any major side effects during the time of the study.

It is unknown how this TB vaccine protects against the advancement of MS, but it appears to stop brain inflammation because lesions were reduced in the individuals who were given the vaccine. It might prove to be helpful for people who already are suffering from the disease.

One theory states that if there were lack of infections during a person’s childhood, this could affect the expansion of the immune system, and that by giving a live vaccine just might help encourage some sort of protective immunity against multiple sclerosis.

The research study recommends against using the vaccine on people who have full-blown MS because, at this time, the long-term effectiveness and safety of the TB treatment is not yet known.

This vaccine is very often given to infants and young children who reside in countries where TB is common. U.S. health officials endorse it only when tuberculosis is likely to occur.

This possible preventative treatment for multiple sclerosis is not likely to be on the United States markets anytime soon.

By Kimberly Ruble

Sources:

FOX News
Business Week News
Decoded Science

We will read your comment immediately so leave a remark!

RSS Guardian Express

  • NBA Playoffs Houston Rockets vs Portland Trail Blazers Preview April 19, 2014
    If star players are what NBA fans want to see in the playoffs, the upcoming series between the Houston Rockets and the Portland Trail Blazers is going to deliver. The two teams had four all-stars between them, and a number of other big name players. Houston edged out Portland for the four seed and home […]
    Brian Moore
  • Students Pitch Moon Colony Plan to NASA, Has Potential April 19, 2014
    On Thursday this week, a group of 40 senior students from Purdue University, presented their moon colonization plans to a very full room. Listening in were a few of NASA’s administrators, eager to collect ideas and provide feedback. Ever since scientists and aeronautics professionals have looked further into the possibility of sustaining human life outside [
    Brad Johnson
  • NBA Playoffs Dominated by Western Conference April 19, 2014
    This NBA season the Western Conference has proven to be more dominant than the Eastern Conference, as the lowest seeded playoff team in the West has a better record than the third seeded team in the East. This story has been a common theme in the NBA playoff picture for the past 15 years thanks […]
    Eric Kummel
  • Green Bay Packers Singles Can Now Find Love [Satire] April 19, 2014
    Fans of the Green Bay Packers can now find love anywhere thanks to the latest dating web site, GreenBayPackerLovers.com. Cheese head singles looking for the love of a significant other who also who is a Green Bay Packer fan finally have a place to go. Obviously this was long overdue. Of course some would argue Wisconsin is […]
    Mick Varner
  • Separatists Reject Ukraine Deal, Will Not Evacuate Government Buildings April 19, 2014
    The US, Russian, Ukraine and the European Union came to an agreement on Thursday in Geneva, Switzerland to put an end to the crisis in Ukraine. The agreement  calls for the pro-Russian separatists to evacuate occupied government buildings and lay down their arms. It also calls for the interim Ukrainian government to restructure its current […]
    Nathaniel Pownell

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 626 other subscribers

Quantcast